Genetically modified microorganisms and methods for producing organic acids

By introducing mutations to enhance the YeeX protein expression and incorporating CoA transferase genes, the production yield of organic acids in microorganisms is significantly improved.

JP7769868B2Active Publication Date: 2025-11-14TORAY INDUSTRIES INC
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
JP2021529758
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2020-05-12
Filing Date
2021-05-11
Publication Date
2025-11-14
Estimated Expiration
2041-05-11

AI Technical Summary

Technical Problem

Existing methods for producing organic acids using microorganisms are limited in yield and efficiency, particularly for chemicals like succinic acid, acetic acid, 3-hydroxyadipic acid, α-hydromuconic acid, and adipic acid.

Method used

Introduce mutations into microorganisms to enhance the expression of a mutant YeeX protein or its homologue, specifically altering the amino acid sequence at key positions, and incorporate genes encoding CoA transferase to improve production capabilities.

Benefits of technology

The genetically modified microorganisms produce organic acids such as succinic acid, acetic acid, 3-hydroxyadipic acid, α-hydromuconic acid, and adipic acid at higher yields compared to unmodified strains.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007769868000001
    Figure 0007769868000001
  • Figure 0007769868000002
    Figure 0007769868000002
  • Figure 0007769868000003
    Figure 0007769868000003
Patent Text Reader

Abstract

A genetically modified microorganism that contains a gene capable of expressing a variant YeeX protein or a homolog thereof, said variant protein having an amino acid sequence derived from the amino acid sequence of a wild type YeeX protein or a homolog thereof by substitution, insertion and / or deletion of one to several amino acids. This genetically modified microorganism has an improved organic acid productivity compared to the microorganism before the genetic modification.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical Field]

[0001] The present invention relates to a genetically modified microorganism capable of producing an organic acid at a high level and a method for producing an organic acid using the genetically modified microorganism. [Background technology]

[0002] Organic acids obtained using microbial fermentation production processes are widely used industrially. For example, succinic acid is used in a variety of products, including pharmaceuticals, food additives, and bath additives, while acetic acid is widely used in foods and reagents. Patent Document 1 discloses a method for producing organic acids containing succinic acid and acetic acid using microorganisms, in which the expression of at least one gene selected from the group consisting of genes encoding phosphoglycerate kinase, phosphofructokinase, glyceraldehyde-3-phosphate dehydrogenase, and fumarate hydratase, genes encoding proteins that constitute the phosphotransferase system, and genes encoding oxidative stress response factors is enhanced compared to an unmodified strain, in order to reduce the influence of fermentation inhibitors when sugar solutions obtained from non-edible resources are used as raw materials.

[0003] Additionally, the six-carbon dicarboxylic acids 3-hydroxyadipic acid (IUPAC name: 3-hydroxyhexanedioic acid), α-hydromuconic acid (IUPAC name: (E)-hex-2-enedioic acid), and adipic acid (IUPAC name: hexanedioic acid) are also attracting industrial attention. These can be used as raw materials for polyamides by polymerizing with polyamines. Furthermore, by adding ammonia to the end of these acids to convert them into lactams, they can also be used alone as raw materials for polyamides. As a method for producing 3-hydroxyadipic acid and other acids using microorganisms, Patent Document 2 discloses genetically modified microorganisms into which nucleic acids encoding polypeptides involved in the production of 3-hydroxyadipic acid and α-hydromuconic acid have been introduced or in which expression of the polypeptides has been enhanced, as well as methods for producing substances using these microorganisms.

[0004] On the other hand, the YeeX protein is classified as a DUF496 family protein. Although there is little publicly known information about the YeeX protein, Non-Patent Document 1 confirms the expression of the E. coli YeeX protein by two-dimensional SDS-PAGE analysis. Patent Document 3 describes the YeeX protein as an example of a protein that functions to assist protein production. Neither document describes the effect of the YeeX protein on organic acid production. [Prior art documents] [Patent documents]

[0005] [Patent Document 1] Japanese Patent Application Publication No. 2017-192325 [Patent Document 2] WO2019 / 107516 [Patent Document 3] US2007 / 0298418 issue [Non-patent literature]

[0006] [Non-Patent Document 1] FEMS Microbiology Letters, vol.169, p.375-382(1998). Summary of the Invention [Problem to be solved by the invention]

[0007] The objective of this study is to improve the yield of products in a method for producing chemical products, such as organic acids, using microorganisms. Specifically, the objective is to introduce mutations into microorganisms to improve their ability to produce chemical products, such as organic acids. [Means for solving the problem]

[0008] The inventors focused on the gene encoding the YeeX protein, the function of which is unknown, and conducted intensive research to solve the above-mentioned problems. As a result, they discovered that microorganisms containing a gene capable of expressing a mutant YeeX protein or its homologue have improved production capabilities for chemicals, such as organic acids, and arrived at the present invention.

[0009] Specifically, the present invention provides the following (1) to (1 4 ) (1) A gene capable of expressing a mutant YeeX protein, which consists of an amino acid sequence that has 90% or more sequence identity with the amino acid sequence represented by SEQ ID NO: 1 and has a mutation in which alanine, the amino acid corresponding to the 84th position in the amino acid sequence of SEQ ID NO: 1, is substituted with another amino acid, and when the gene is introduced into a microorganism of the genus Escherichia that is capable of producing succinic acid, acetic acid, 3-hydroxyadipic acid, α-hydromuconic acid, and / or adipic acid, the gene has the function of improving the ability of the microorganism to produce succinic acid, acetic acid, 3-hydroxyadipic acid, α-hydromuconic acid, and / or adipic acid compared to the microorganism before introduction. The gene encoding CoA transferase is introduced into the vector. Ta, E A genetically modified microorganism belonging to the genus Scherichia. (2) A genetically modified microorganism belonging to the genus Serratia, comprising a gene capable of expressing a mutant YeeX protein having the amino acid sequence shown in SEQ ID NO: 2 and a mutation in which the alanine at position 87 in the amino acid sequence of SEQ ID NO: 2 is substituted with another amino acid, and which, when introduced into a Serratia microorganism capable of producing succinic acid, acetic acid, 3-hydroxyadipic acid, α-hydromuconic acid and / or adipic acid, has the function of improving the ability of the microorganism to produce succinic acid, acetic acid, 3-hydroxyadipic acid, α-hydromuconic acid and / or adipic acid compared to the microorganism before introduction, and into which a gene encoding CoA transferase has been introduced. (3) The mutant YeeX protein The quality , the amino acid sequence of SEQ ID NO: 1 of The alanine corresponding to position 84 is Balin, The genetically modified microorganism according to (1), having a mutation substituted with leucine, phenylalanine, isoleucine, or methionine. (4) The genetically modified microorganism according to (2), wherein the mutant YeeX protein has a mutation in which the alanine at position 87 in the amino acid sequence of SEQ ID NO: 2 is replaced with valine, leucine, phenylalanine, isoleucine, or methionine. (5) The mutant YeeX protein Quality (1) Having expressible genes on the genome Any one of (4) A genetically modified microorganism described in (6) On the genome Y eeX protein Quality The expressible gene is the mutant YeeX protein. Quality Mutation or substitution into an expressible gene ( 5 ) A genetically modified microorganism described in (7)( Any one of items 1) to (6) A method for producing an organic acid, comprising culturing the genetically modified microorganism described in 1 above in a medium containing a carbon source as a fermentation raw material. (8) The organic acid is succinic acid, acetic acid, 3-hydroxyadipic acid, α-hydromuconic acid and / or adipic acid, 7 ) A method for producing an organic acid according to the above. (9) A gene capable of expressing a mutant YeeX protein, which consists of an amino acid sequence that has 90% or more sequence identity with the amino acid sequence represented by SEQ ID NO: 1 and has a mutation in which alanine, the amino acid corresponding to the 84th position in the amino acid sequence of SEQ ID NO: 1, is substituted with another amino acid, and which, when introduced into an Escherichia microorganism capable of producing succinic acid, acetic acid, 3-hydroxyadipic acid, α-hydromuconic acid, and / or adipic acid, has the function of improving the ability of the microorganism to produce succinic acid, acetic acid, 3-hydroxyadipic acid, α-hydromuconic acid, and / or adipic acid compared to before introduction. Contains 、E A genetically modified microorganism belonging to the genus Scherichia. (10) A genetically modified microorganism belonging to the genus Serratia, comprising a gene capable of expressing a mutant YeeX protein having the amino acid sequence shown in SEQ ID NO: 2 and a mutation in which the alanine at position 87 in the amino acid sequence of SEQ ID NO: 2 is replaced with another amino acid, and which, when introduced into a Serratia microorganism capable of producing succinic acid, acetic acid, 3-hydroxyadipic acid, α-hydromuconic acid and / or adipic acid, has the function of improving the ability of the microorganism to produce succinic acid, acetic acid, 3-hydroxyadipic acid, α-hydromuconic acid and / or adipic acid compared to the microorganism before introduction. (11) The mutant YeeX protein The quality , the alanine corresponding to the 84th amino acid in the amino acid sequence of SEQ ID NO: 1 is Balin, leucine, phenylalanine, isoleucine, or methionine substitution mutations ( 9 ) A genetically modified microorganism described in (12) The genetically modified microorganism according to (10), wherein the mutant YeeX protein has a mutation in which the alanine at position 87 in the amino acid sequence of SEQ ID NO: 2 is replaced with valine, leucine, phenylalanine, isoleucine, or methionine. (13)( Any one of items 9) to (12) A method for producing an organic acid, comprising culturing the genetically modified microorganism described in 1 above in a medium containing a carbon source as a fermentation raw material. (14) The method for producing an organic acid according to (13), wherein the organic acid is succinic acid, acetic acid, 3-hydroxyadipic acid, α-hydromuconic acid, and / or adipic acid. [Effects of the Invention]

[0010] The genetically modified microorganism of the present invention contains a gene capable of expressing a mutant YeeX protein or its homologue, and is therefore capable of producing chemical products, such as organic acids, at a higher yield than the microorganism before genetic modification. DETAILED DESCRIPTION OF THE INVENTION

[0011] The present invention will be described in more detail below, but the present invention is not limited to the following embodiments and can be implemented with various modifications within the scope of the gist of the present invention.

[0012] The genetically modified microorganism of the present invention comprises a gene capable of expressing a mutant YeeX protein or a homolog thereof. The method for producing an organic acid of the present invention comprises culturing the genetically modified microorganism.

[0013] The YeeX protein belongs to the DUF496 family of proteins. "yeeX" refers to the gene encoding the YeeX protein. Based on the secondary structure prediction of the amino acid sequence of SEQ ID NO: 1, the results of HHPred (Homology detection & structure prediction by HMM-HMM comparison) search suggest that the YeeX protein has a structure similar to that of a transcription factor.

[0014] A homolog of the YeeX protein refers to a wild-type protein that has a high amino acid sequence identity with the identified YeeX protein and is presumed to have a similar function or structure to the YeeX protein. The YeeX protein used in the present invention preferably has a sequence identity of 50% or more, more preferably 55% or more, even more preferably 70% or more, even more preferably 80% or more, even more preferably 90% or more, and particularly preferably 95% or more, to the amino acid sequence of SEQ ID NO: 1.

[0015] Examples of the YeeX protein or its homologues include a YeeX protein derived from Escherichia coli (NCBI Protein ID: NP_416511, SEQ ID NO: 1), a homologue of the YeeX protein derived from Serratia grimesii (NCBI Protein ID: HCJ99940, SEQ ID NO: 2), a homologue of the YeeX protein derived from Acinetobacter baumannii (NCBI Protein ID: AAL09094, SEQ ID NO: 3), a homologue of the YeeX protein derived from Actinobacillus succinogenes (NCBI Protein ID: WP_012072666, SEQ ID NO: 4), a homologue of the YeeX protein derived from Aerobacter cloacae (NCBI Protein ID: WP_115875767, SEQ ID NO: 5), a homologue of the YeeX protein derived from Basfia succiniciproducens (Protein ID: WP_011200744, SEQ ID NO: 6), and Hafnia Examples include a homolog of the YeeX protein derived from Pseudomonas paralvei (Protein ID: WP_004089583, SEQ ID NO: 7), a homolog of the YeeX protein derived from Pseudomonas aeruginosa (Protein ID: MXH34489, SEQ ID NO: 8), and a homolog of the YeeX protein derived from Shimwellia blattae (Protein ID: WP_002439990, SEQ ID NO: 9).

[0016] In the present invention, "sequence identity" refers to the percentage of identical amino acids or bases in the entire overlapping amino acid sequence (including the amino acid that serves as the translation initiation point) or base sequence (including the initiation codon) in optimal alignment of two amino acid sequences or base sequences, with or without gaps, and is calculated using formula (1). Sequence identity can be easily determined using BLAST (Basic Local Alignment Search Tool), an algorithm commonly used in this field. For example, BLAST is available to anyone from websites such as NCBI (National Center for Biotechnology Information) and KEGG (Kyoto Encyclopedia of Genes and Genomes), and sequence identity can be easily determined using default parameters.

[0017] Sequence identity (%) = number of matches (ignoring gaps) / length of shorter sequence (length excluding gaps) × 100... Equation (1).

[0018] When the sequence identity between the amino acid sequences set forth in SEQ ID NOS: 1 to 9 was calculated using the Genetyx function (% Identity Matrix) according to formula (1), the lowest sequence identity value was 54.46% for SEQ ID NOS: 4 and 9, and the amino acid sequences set forth in SEQ ID NOS: 1 to 9 have at least 50% sequence identity with each other. The results of calculating the sequence identity using Genetyx are shown in Table 1. In Table 1 below, the numbers on the far left indicate the sequence numbers.

[0019] [Table 1]

[0020] The gene encoding the YeeX protein or a homolog thereof is not particularly limited as long as it has a nucleotide sequence that can be translated into the amino acid sequences set forth in SEQ ID NOS: 1 to 9 or the amino acid sequences of these homologs, and can be determined with reference to the codons (standard genetic code) corresponding to each amino acid. In this case, the nucleotide sequence may be redesigned to use codons that are commonly used in the host microorganism used in the present invention.

[0021] Specific examples of the nucleotide sequences of genes encoding polypeptides having the amino acid sequences set forth in SEQ ID NOs: 1 and 2 include the nucleotide sequences set forth in SEQ ID NOs: 10 and 11, respectively.

[0022] One characteristic of the YeeX protein and its homologs is that the region corresponding to amino acid residues 74-100 in the amino acid sequence of SEQ ID NO: 1 is predicted to form an α-helical structure, and the sequence identity between species is high. Protein secondary structure can be easily determined by analyzing the amino acid sequence using a well-known web application such as Quick2D. Another characteristic of the YeeX protein and its homologs is that the amino acid residue corresponding to position 84 in the amino acid sequence of SEQ ID NO: 1 is alanine. Multiple alignment of the YeeX proteins and their homologs having the amino acid sequences of SEQ ID NOs: 1-9 shown in Table 2 demonstrates that the region corresponding to amino acid residues 74-100, predicted to form an α-helical structure in the amino acid sequence of SEQ ID NO: 1, and the alanine corresponding to amino acid residue 84 are conserved.

[0023] [Table 2]

[0024] The mutant YeeX protein or its homologue in the present invention is characterized by having one to several, specifically 1 to 10, preferably 1 to 5, more preferably 1 to 3, even more preferably 1 to 3, still more preferably 1 or 2, and particularly preferably 1 amino acid substitution, insertion, and / or deletion in the amino acid sequence of the wild-type YeeX protein or its homologue. The mutation site is not particularly limited, but is preferably a region corresponding to amino acid residues 74 to 100 in the amino acid sequence of SEQ ID NO: 1, which has high interspecies sequence identity and is predicted to form an α-helical structure, more preferably a region corresponding to amino acid residues 74 to 94, even more preferably a region corresponding to amino acid residues 75 to 88, even more preferably a region corresponding to amino acid residues 82 to 88, and particularly preferably an alanine corresponding to amino acid residue 84.

[0025] When the mutation site in the mutant YeeX protein or its homologue is an alanine corresponding to the 84th amino acid residue in the amino acid sequence of SEQ ID NO: 1, it is preferable that the mutation be substituted with an amino acid other than alanine. The amino acid other than alanine may be any amino acid residue, but is preferably the hydrophobic amino acid residues valine, leucine, isoleucine, proline, glycine, methionine, or phenylalanine, more preferably valine, leucine, or isoleucine, and even more preferably valine.

[0026] The method for expressing the mutant YeeX protein or its homologue in the genetically modified microorganism of the present invention is not particularly limited, and may be carried out by known methods such as introducing a mutation into a gene encoding the endogenous YeeX protein or its homologue, or by using an expression vector capable of autonomous replication within the microorganism. MutantSpecific examples of methods include introducing a gene encoding the YeeX protein or a homologue thereof, introducing a gene encoding a mutant YeeX protein or a homologue thereof using techniques such as homologous recombination into the genome of a microorganism, or replacing an endogenous gene encoding a YeeX protein or a homologue thereof with a gene encoding a mutant YeeX protein or a homologue thereof. However, for the genetically modified microorganism of the present invention, preferred methods include incorporating the gene into an expression vector capable of autonomous replication within the microorganism and introducing it into the microorganism, or replacing the gene encoding the mutant YeeX protein or a homologue thereof into the genome of the host microorganism by introducing a mutation into the gene encoding the endogenous YeeX protein or a homologue thereof or using techniques such as homologous recombination into the genome of the microorganism.

[0027] The microorganism used in the present invention is not particularly limited as long as it is a genetically modified microorganism having a gene encoding a mutant YeeX protein or a homologue of a mutant YeeX protein, but is preferably a microorganism capable of producing a chemical product, more preferably a microorganism capable of producing an organic acid or amino acid, and even more preferably a microorganism capable of producing an organic acid. Specifically, it is preferably a microorganism selected from the group consisting of the genus Serratia, Escherichia, Actinobacillus, Basfia, Pseudomonas, Hafnia, Acinetobacter, Shimwellia or Aerobacter, more preferably a microorganism belonging to the genus Serratia, Escherichia, Actinobacillus or Basfia, and particularly preferably a microorganism belonging to the genus Serratia or Escherichia.

[0028] When a genetically modified microorganism of the present invention has the ability to produce an organic acid, it is characterized by having superior organic acid productivity compared to a microorganism prior to genetic modification to contain a gene capable of expressing a mutant YeeX protein or its homolog. Here, "superior organic acid productivity" refers to the production of an organic acid at a higher yield than a microbial strain containing a gene capable of expressing only the wild-type YeeX protein of SEQ ID NO: 1 under the same host microorganism or fermentation conditions, or a microbial strain lacking the gene capable of expressing the YeeX protein. In the method for producing an organic acid using a genetically modified microorganism of the present invention, the acetic acid yield is calculated according to Equation (2). The succinic acid yield, 3-hydroxyadipic acid yield, α-hydromuconic acid yield, and adipic acid yield are calculated by replacing acetic acid in Equation (2) with succinic acid, 3-hydroxyadipic acid, α-hydromuconic acid, or adipic acid, respectively.

[0029] Yield (%) = acetic acid (mol) / carbon source consumption (mol) × 100 Equation (2).

[0030] When the gene encoding the mutant YeeX protein to be expressed in the present invention is incorporated into an expression vector, it is preferable that the expression vector be composed of a promoter, a ribosome binding sequence, a gene encoding the protein to be expressed, and a transcription termination sequence.

[0031] When a gene encoding a mutant YeeX protein is integrated into the genome of a microorganism, the nucleic acid to be integrated into the genome preferably comprises a promoter, a ribosome binding sequence, a gene encoding the protein to be expressed, and a transcription termination sequence, and the gene encoding the mutant YeeX protein or its homolog is integrated to replace the wild-type YeeX protein or its homolog originally possessed by the microorganism. A gene for regulating promoter activity may also be included.

[0032] The promoter used in the present invention is not particularly limited as long as it can express the enzyme in a microorganism, and examples thereof include the gap promoter, trp promoter, lac promoter, tac promoter, and T7 promoter.

[0033] When an expression vector is used to introduce a gene or express a protein in the present invention, it is not particularly limited as long as it is capable of autonomous replication in the microorganism, but examples include pBBR1MCS vector, pBR322 vector, pMW vector, pET vector, pRSF vector, pCDF vector, pACYC vector, and derivatives of the above-mentioned vectors.

[0034] In the present invention, when a nucleic acid for genome integration is used to introduce a gene or express a protein, the introduction is carried out using site-specific homologous recombination. The method of site-specific homologous recombination is not particularly limited, but examples include a method using λ Red recombinase and the sacB gene (Biosci. Biotechnol. Biochem. 2007; 71(12): 2905-2911) and a method using λ Red recombinase and FLP recombinase (Proc. Natl. Acad. Sci. USA 2000; 97(12): 6640-6645).

[0035] The method for introducing an expression vector or a nucleic acid to be integrated into a genome is not particularly limited as long as it is a method for introducing a nucleic acid into a microorganism, and examples thereof include electroporation (J. Bacteriol. 1988; 170: 2796-2801.) and calcium ion method (J. Mol. Biol. 1970; 53(1): 159-162.).

[0036] When a genetically modified microorganism of the present invention has the ability to produce an organic acid, the organic acid produced is not particularly limited as long as it can be produced and accumulated by the microorganism in the medium, but specific examples include carboxylic acids such as acetic acid, succinic acid, formic acid, pyruvic acid, fumaric acid, malic acid, oxaloacetic acid, citric acid, levulinic acid, 3-oxoadipate, 3-hydroxyadipic acid, α-hydromuconic acid, adipic acid, and 2,5-furandicarboxylic acid. Among these carboxylic acids, acetic acid, succinic acid, 3-hydroxyadipic acid, α-hydromuconic acid, and / or adipic acid are preferred because the effects of the present invention are most pronounced. In this specification, 3-hydroxyadipic acid may be abbreviated as 3HA, α-hydromuconic acid as HMA, and adipic acid as ADA.

[0037] The organic acids are produced by the reaction pathways inherent in the genetically modified microorganisms of the present invention. In particular, 3HA, HMA, and ADA are produced by the reaction pathways shown in Scheme 1 below. For the fermentative production of these organic acids, microbial strains expressing enzymes that catalyze Reactions A, B, C, D, E, F, and G are used.

[0038] [ka]

[0039] Scheme 1 above shows an example of the reaction pathways required to produce 3HA, HMA, and / or ADA. Here, Reaction A represents the reaction of generating 3-oxoadipyl-CoA and coenzyme A from acetyl-CoA and succinyl-CoA. Reaction B represents the reaction of generating 3-hydroxyadipyl-CoA from 3-oxoadipyl-CoA. Reaction C represents the reaction of generating 2,3-dehydroadipyl-CoA from 3-hydroxyadipyl-CoA. Reaction D represents the reaction of generating adipyl-CoA from 2,3-dehydroadipyl-CoA. Reaction E represents the reaction of generating 3HA from 3-hydroxyadipyl-CoA. Reaction F represents the reaction of generating HMA from 2,3-dehydroadipyl-CoA. Reaction G represents the reaction of generating ADA from adipyl-CoA.

[0040] Specific examples of enzymes that catalyze these reactions include acyltransferase, which catalyzes reaction A; 3-oxoadipyl-CoA reductase, which catalyzes reaction B; enoyl-CoA hydratase, which catalyzes reaction C; enoyl-CoA reductase, which catalyzes reaction D; and CoA transferase, which catalyzes reactions E, F, and G.

[0041] A specific example of a gene encoding an enzyme that catalyzes reaction A is the acyltransferase pcaF derived from Pseudomonas putida KT2440 strain (NCBI Gene ID: 1041755, SEQ ID NO: 13).

[0042] A specific example of a gene encoding an enzyme that catalyzes reaction B is 3-oxoadipyl-CoA reductase derived from Serratia marcescens ATCC13880 strain (NCBI Gene ID: JMPQ01000047.1, SEQ ID NO: 14).

[0043] A specific example of a gene encoding an enzyme that catalyzes reaction C is enoyl-CoA hydratase paaF derived from Pseudomonas putida KT2440 strain (NCBI Gene ID: 1046932, SEQ ID NO: 15).

[0044] A specific example of a gene encoding an enzyme that catalyzes reaction D is enoyl-CoA reductase dcaA derived from Acinetobacter baylyi strain ADP1 (NCBI-Protein ID: AAL09094.1, SEQ ID NO: 16).

[0045] A specific example of a gene encoding an enzyme that catalyzes reactions E, F, and G is a continuous sequence containing the entire length of pcaI and pcaJ derived from Pseudomonas putida KT2440 strain (NCBI Gene IDs: 1046613 and 1046612; SEQ ID NOs: 17 and 18). The polypeptides encoded by pcaI and pcaJ form a complex to catalyze reactions E, F, and G.

[0046] The genes encoding the enzymes that catalyze reactions A to G may be genes that the microorganisms already possess, or may be artificially introduced. The method for introducing the genes is not particularly limited, and methods that can be used include incorporating the genes into an expression vector that can autonomously replicate within the microorganism and then introducing the genes into the microorganism, or incorporating the genes into the genome of the microorganism.

[0047] In the present invention, the genetically modified microorganism is cultured in a medium, preferably a liquid medium, containing a carbon source that can be utilized by ordinary microorganisms as a fermentation raw material to produce an organic acid. In addition to the carbon source that can be utilized by the genetically modified microorganism, a medium containing an appropriate amount of a nitrogen source, inorganic salts, and, as needed, organic trace nutrients such as amino acids and vitamins is used. Either a natural or synthetic medium can be used as long as it contains the above-mentioned nutrient sources.

[0048] The fermentation raw material is a raw material that can be metabolized by the genetically modified microorganism. "Metabolism" refers to the conversion of a compound taken up by the microorganism from outside the cell or produced by another chemical substance inside the cell into another chemical substance through an enzymatic reaction. Sugars are preferably used as the carbon source. In addition to sugars, any carbon source that can be used by the genetically modified microorganism as a sole carbon source for growth can also be preferably used. Specific examples of preferred carbon sources include monosaccharides such as glucose, fructose, galactose, mannose, xylose, and arabinose, disaccharides such as sucrose formed by combining these monosaccharides, polysaccharides, and starch saccharification solutions, molasses, and cellulose-containing biomass saccharification solutions containing these sugars.

[0049] Furthermore, when producing 3HA, HMA, and / or ADA, adding succinic acid, a substrate for CoA transferase, in addition to the sugars listed above, enables efficient production of 3-hydroxyadipic acid, α-hydromuconic acid, and / or adipic acid.

[0050] The carbon sources listed above may be used alone or in combination. The concentrations of the carbon sources in the medium are not particularly limited and can be appropriately set depending on the type of carbon source, etc. Preferably, the sugars are 5 to 300 g / L and the succinic acid is 0.1 to 100 g / L.

[0051] Examples of nitrogen sources that can be used include ammonia gas, ammonia water, ammonium salts, urea, nitrates, and other supplementary organic nitrogen sources such as oil cakes, soybean hydrolysate, casein hydrolysate, other amino acids, vitamins, corn steep liquor, yeast or yeast extract, meat extract, peptides such as peptone, various fermentation bacteria and their hydrolysates, etc. The concentration of the nitrogen source in the medium is not particularly limited, but is preferably 0.1 to 50 g / L.

[0052] As inorganic salts used in culturing the genetically modified microorganism, for example, phosphate salts, magnesium salts, calcium salts, iron salts, manganese salts, etc. can be added as appropriate.

[0053] The culture conditions for the genetically modified microorganism to produce an organic acid are set by appropriately adjusting or selecting the medium with the above-mentioned component composition, culture temperature, stirring speed, pH, aeration amount, inoculation amount, etc. depending on the type of the genetically modified microorganism, external conditions, etc. If foaming occurs during liquid culture, an antifoaming agent such as mineral oil, silicone oil, or surfactant can be appropriately added to the medium.

[0054] After the organic acid has been produced in the culture of the genetically modified microorganism to a recoverable amount, the produced product can be recovered. The recovery, e.g., isolation, of the produced product can be carried out in accordance with a general method of stopping the culture when the accumulation amount has reached a suitable level and collecting a fermentation product from the culture. Specifically, the product can be isolated from the culture by separating the bacterial cells by centrifugation, filtration, or the like, followed by column chromatography, ion exchange chromatography, activated carbon treatment, crystallization, membrane separation, distillation, or the like. More specifically, the product can be isolated from the culture by adding an acidic component to the salt of the product and recovering the precipitate; by concentrating the culture using a reverse osmosis membrane or evaporator to remove water and increase the concentration of the product, followed by recovery by distillation; by precipitating crystals of the product and / or the salt of the product by cooling crystallization or adiabatic crystallization, and then obtaining crystals of the product and / or the salt of the product by centrifugation, filtration, or the like; or by adding alcohol to the culture and recovering the precipitate. The relevant Examples of methods include, but are not limited to, esterifying the product, recovering the ester by distillation, and then obtaining the product by hydrolysis. These recovery methods can be appropriately selected and optimized depending on the physical properties of the product. [Example]

[0055] (Reference Example 1) Preparation of nucleic acid for integrating mutant YeeX protein homologue described in SEQ ID NO: 12 into the genome of Serratia grimesii (S. grimesii) NBRC13537 strain A method using λ Red recombinase and the sacB gene was used to introduce a gene encoding a mutant YeeX protein homolog into the genome of an S. grimesii strain. The nucleic acid sequence required for integrating the nucleic acid into the genome was obtained by nucleic acid synthesis (Genewiz). The nucleic acid sequence included an 840-b upstream region of the gene encoding the wild-type YeeX protein homolog on the S. grimesii genome, the sacB gene, a kanamycin resistance gene, and an 840-b downstream region of the gene encoding the wild-type YeeX protein homolog (SEQ ID NO: 19). Primers were designed (SEQ ID NOs: 20 and 21) for PCR amplification of the nucleic acid fragment obtained by nucleic acid synthesis, and PCR was performed according to standard methods. The resulting fragment was purified by agarose gel electrophoresis and a nucleic acid column purification kit (Cytiva) and used to generate mutant strains.

[0056] (Reference Example 2) Preparation of Plasmid 1 The vector pBBR1MCS-2 (ME Kovach, (1995), Gene 166: 175-176), which is capable of autonomous replication in E. coli and S. grimesii, was digested with XhoI to obtain pBBR1MCS-2 / XhoI. To incorporate a constitutive expression promoter into this vector, primers (SEQ ID NOs: 23 and 24) were designed to PCR amplify a 200-b region (SEQ ID NO: 22) upstream of gapA (NCBI Gene ID: NC_000913.3) using the genomic DNA of Escherichia coli (E. coli) str. K-12 substr. MG1655 as a template, and PCR was performed according to standard procedures. The resulting fragment and pBBR1MCS-2 / XhoI were ligated using the In-Fusion HD Cloning Kit (Takara Bio Inc.) and transformed into E. coli DH5α. The plasmid was extracted from the resulting recombinant strain, and the nucleotide sequence was confirmed by a standard method. The plasmid was designated pBBR1MCS-2::Pgap. pBBR1MCS-2::Pgap was then cleaved with ScaI to obtain pBBR1MCS-2::Pgap / ScaI.

[0057] To amplify the gene encoding the enzyme that catalyzes reaction A, primers (SEQ ID NOs: 25 and 26) were designed to PCR amplify the full length of the acyltransferase gene pcaF (NCBI Gene ID: 1041755, SEQ ID NO: 13) using the genomic DNA of Pseudomonas putida KT2440 strain as a template, and PCR was performed according to standard methods. The resulting fragment and pBBR1MCS-2::Pgap / ScaI were ligated using the In-Fusion HD Cloning Kit and introduced into the E. coli strain DH5α. The plasmid was extracted from the resulting recombinant strain, and the nucleotide sequence was confirmed by standard methods. The resulting plasmid was designated pBBR1MCS-2::AT.

[0058] Next, pBBR1MCS-2::AT was digested with HpaI to obtain pBBR1MCS-2::AT / HpaI. To amplify the genes encoding the enzymes catalyzing reactions E, F, and G, primers (SEQ ID NOS: 27 and 28) were designed to PCR amplify a continuous sequence containing the full-length CoA transferase genes pcaI and pcaJ (NCBI GeneIDs: 1046613 and 1046612, SEQ ID NOS: 17 and 18) using the genomic DNA of Pseudomonas putida KT2440 as a template. PCR was performed according to standard methods. The resulting fragment and pBBR1MCS-2::AT / HpaI were ligated using the In-Fusion HD Cloning Kit and introduced into E. coli DH5α. The plasmid was extracted from the resulting recombinant strain, and the nucleotide sequence was confirmed by standard methods. This plasmid was designated pBBR1MCS-2::ATCT.

[0059] pBBR1MCS-2::ATCT was digested with ScaI to obtain pBBR1MCS-2::ATCT / ScaI. To amplify the nucleic acid encoding 3-oxoadipyl-CoA reductase, which catalyzes reaction B, primers (SEQ ID NOs: 29 and 30) for amplifying the nucleic acid set forth in SEQ ID NO: 14 were designed using the genomic DNA of Serratia marcescens ATCC13880 strain as a template, and PCR was performed according to standard methods. The resulting fragment and pBBR1MCS-2::ATCT / ScaI were ligated using the In-Fusion HD Cloning Kit (Takara Bio Inc.) and introduced into E. coli DH5α. The plasmid was extracted from the resulting recombinant strain, and the nucleotide sequence was confirmed by standard methods. This plasmid was designated as Plasmid 1.

[0060] (Reference Example 3) Preparation of Plasmid 2 pMW119 (Nippon Gene) was digested with SacI to obtain pMW119 / SacI. To incorporate a constitutive expression promoter into this vector, primers (SEQ ID NOs: 31 and 32) were designed to PCR amplify a 200-b region (SEQ ID NO: 22) upstream of gapA (NCBI Gene ID: NC_000913.3) using the genomic DNA of E. coli str. K-12 substr. MG1655 as a template, and PCR was performed according to standard methods. The resulting fragment and pMW119 / SacI were ligated using the In-Fusion HD Cloning Kit (Takara Bio Inc.) and introduced into E. coli DH5α. The plasmid was extracted from the resulting recombinant strain, and the nucleotide sequence was confirmed using standard methods. The resulting plasmid was designated pMW119::Pgap.

[0061] Next, pMW119::Pgap was digested with SphI to obtain pMW119::Pgap / SphI. To amplify the gene encoding the enzyme catalyzing reaction C, primers (SEQ ID NOs: 33 and 34) were designed to PCR amplify the full-length enoyl-CoA hydratase gene paaF (NCBI Gene ID: 1046932, SEQ ID NO: 15) using the genomic DNA of Pseudomonas putida KT2440 strain as a template, and PCR was performed according to standard methods. The resulting fragment and pMW119::Pgap / SphI were ligated using the In-Fusion HD Cloning Kit (Takara Bio Inc.) and introduced into E. coli DH5α. The plasmid was extracted from the resulting recombinant strain, and the nucleotide sequence was confirmed using standard methods. The resulting plasmid was designated pMW119::EH.

[0062] pMW119::EH was digested with HindIII to obtain pMW119::EH / HindIII. To amplify the gene encoding the enzyme catalyzing reaction D, primers (SEQ ID NOs: 35 and 36) were designed to PCR amplify the full-length dcaA gene (NCBI-Protein ID: AAL09094.1, SEQ ID NO: 16) derived from Acinetobacter baylyi ADP1 strain, and PCR was performed according to standard methods. The resulting fragment and pMW119::EH / HindIII were ligated using the In-Fusion HD Cloning Kit (Takara Bio Inc.) and introduced into E. coli DH5α. The plasmid was extracted from the resulting recombinant strain, and the nucleotide sequence was confirmed by standard methods. This plasmid was designated plasmid 2.

[0063] (Reference Example 4) Preparation of a plasmid (plasmid 3) for expressing a mutant YeeX protein homologue set forth in SEQ ID NO: 12 pMW119::Pgap described in Reference Example 3 was cleaved with KpnI to obtain pMW119::Pgap / KpnI. Primers were designed (SEQ ID NOs: 38 and 39) for PCR amplification of the full-length gene encoding the mutant YeeX protein homolog described in SEQ ID NO: 12 (SEQ ID NO: 37), and PCR was performed according to standard methods. The resulting fragment and pMW119::Pgap / KpnI were ligated using the In-Fusion HD Cloning Kit and introduced into E. coli DH5α. The plasmid was extracted from the resulting recombinant strain, and the nucleotide sequence was confirmed by standard methods. This plasmid was designated plasmid 3.

[0064] (Reference Example 5) Preparation of nucleic acid for incorporating mutant YeeX described in SEQ ID NO: 44 into the genome of Escherichia coli (E. coli) MG1655 strain A method using λ Red recombinase and the sacB gene was used to introduce the mutant YeeX gene into the genome of the E. coli MG1655 strain. The nucleic acid sequence required for integrating the nucleic acid into the genome was obtained by nucleic acid synthesis (Genewiz). The nucleic acid sequence included a 500-b upstream region of the wild-type YeeX gene on the E. coli genome, the sacB gene, a kanamycin resistance gene, and a 500-b downstream region of the wild-type YeeX gene (SEQ ID NO: 45). Primers were designed (SEQ ID NOs: 46 and 47) to amplify the nucleic acid fragment obtained by nucleic acid synthesis, and PCR was performed according to standard methods. The resulting fragment was purified by agarose gel electrophoresis and a nucleic acid column purification kit (Cytiva) and used to generate the mutant strain.

[0065] (Reference Example 6) Preparation of a plasmid (plasmid 4) for expressing mutant YeeX described in SEQ ID NO: 44 The pCDF-1b plasmid was digested with KpnI to obtain pCDF-1b / KpnI. Primers were designed (SEQ ID NOs: 49 and 50) to PCR amplify the gene encoding the mutant YeeX protein homolog set forth in SEQ ID NO: 44 and the full-length 500b upstream and 500b downstream regions of the gene (SEQ ID NO: 48), and PCR was performed according to standard methods. The resulting fragment and pCDF-1b / KpnI were ligated using the In-Fusion HD Cloning Kit and introduced into E. coli DH5α. The plasmid was extracted from the resulting recombinant strain, and the nucleotide sequence was confirmed using standard methods. This plasmid was designated Plasmid 4.

[0066] (Comparative Example 1) Cultivation of an S. grimeii strain carrying a gene encoding the protein set forth in SEQ ID NO: 2 As a parent strain carrying the wild-type YeeX protein homologue described in SEQ ID NO: 2, we used Serratia grimesii NBRC13537, in which the gene encoding the glucose transporter PtsG (SEQ ID NO: 40) and the genes encoding the pyruvate kinases PykF and PykA (SEQ ID NOs: 41 and 42) had been deleted.

[0067] A loopful of S. grimesii parent strain was inoculated into 5 mL of LB medium (Bacto tryptone (Difco Laboratories) 10 g / L, Bacto yeast extract (Difco Laboratories) 5 g / L, sodium chloride 5 g / L) adjusted to pH 7, and cultured at 30°C with shaking at 120 min-1 for 18 hours. 0.15 mL of the culture medium was added to 15 mL of medium I (glucose 10 g / L, ammonium sulfate 1 g / L, potassium phosphate 50 mM, magnesium sulfate 0.025 g / L, iron sulfate 0.0625 mg / L, manganese sulfate 2.7 mg / L, calcium chloride 0.33 mg / L, sodium chloride 1.25 g / L, Bacto tryptone 2.5 g / L, Bacto yeast extract 1.25 g / L) adjusted to pH 6.5 in a screw-capped test tube, and the mixture was cultured at 30°C with shaking at 120 min-1 for 48 hours.

[0068] The supernatant obtained by centrifuging the culture medium and separating the cells was passed through a Millex-GV membrane (0.22 μm, PVDF, Merck), and the permeate was analyzed by HPLC and LC-MS / MS. The results of quantitative analysis of the organic acids accumulated in the culture supernatant and the yield of the organic acids calculated using formula (2) are shown in Table 3.

[0069] [Quantitative analysis conditions for glucose, acetic acid, and succinic acid by HPLC] HPLC: Shimadzu Prominence (Shimadzu Corporation) Column: Shodex Sugar SH1011 (Showa Denko K.K.), length 300 mm, inner diameter 8 mm, particle size 6 μm Mobile phase: 0.05M sulfuric acid aqueous solution Flow rate: 0.6mL / min Column temperature: 65℃ Detector: RI.

[0070] [Quantitative analysis conditions for 3HA, HMA, and ADA by LC-MS / MS] HPLC: 1290 Infinity (Agilent Technologies) Column: Synergi hydro-RP (Phenomenex), length 100 mm, inner diameter 3 mm, particle size 2.5 μm Mobile phase: 0.1% formic acid aqueous solution / methanol = 70 / 30 Flow rate: 0.3mL / min Column temperature: 40℃ LC detector: DAD (210 nm) MS / MS: Triple-Quad LC / MS (Agilent Technologies) Ionization method: ESI negative mode.

[0071] (Comparative Example 2) Preparation and cultivation of S. grimesii / yeeX-deficient strain lacking the gene encoding the YeeX protein The pKD46 plasmid required for expressing λ Red recombinase was introduced into the S. grimesii strain described in Comparative Example 1 by electroporation. After introduction, the strain was cultured at 30°C on LB agar medium containing 500 μg / mL of ampicillin. The nucleic acid fragment prepared in Reference Example 1 was introduced into the resulting strain by electroporation. After introduction, the strain was cultured at 30°C on LB agar medium containing 25 μg / mL of kanamycin. The resulting recombinant strain was an S. grimesii / pKD46 / yeeX-deficient strain in which the full-length gene sequence encoding the YeeX protein homolog was replaced with a recombination cassette sequence. To remove the pKD46 plasmid from the S. grimesii / pKD46 / yeeX-deficient strain, one loopful of the strain was inoculated into 5 mL of LB medium (10 g / L Bacto tryptone (Difco Laboratories), 5 g / L Bacto yeast extract (Difco Laboratories), 5 g / L sodium chloride) and cultured at 37°C for 48 hours with shaking at 120 min-1. Ten μL of the culture was cultured on LB agar medium at 30°C, and colonies lacking ampicillin resistance were selected to obtain the S. grimesii / yeeX-deficient strain.

[0072] One loopful of the strain was inoculated into 5 mL of LB medium (10 g / L Bacto tryptone (Difco Laboratories), 5 g / L Bacto yeast extract (Difco Laboratories), 5 g / L sodium chloride) containing 25 μg / mL kanamycin adjusted to pH 7, and cultured at 30°C for 18 hours with shaking at 120 min-1. 0.15 mL of the culture medium was added to 15 mL of Medium I (glucose 10 g / L, ammonium sulfate 1 g / L, potassium phosphate 50 mM, magnesium sulfate 0.025 g / L, iron sulfate 0.0625 mg / L, manganese sulfate 2.7 mg / L, calcium chloride 0.33 mg / L, sodium chloride 1.25 g / L, Bacto tryptone 2.5 g / L, Bacto yeast extract 1.25 g / L) containing 25 μg / mL kanamycin and adjusted to pH 6.5 in a screw-capped test tube, and the mixture was cultured at 30°C with shaking at 120 min-1 for 48 hours.

[0073] The supernatant obtained by centrifuging the culture medium and separating the cells was passed through a Millex-GV membrane (0.22 μm, PVDF, Merck), and the permeate was analyzed by HPLC and LC-MS / MS. The results of quantitative analysis of the organic acids accumulated in the culture supernatant and the yield of the organic acids calculated using formula (2) are shown in Table 3.

[0074] (Example 1) Construction and cultivation of S. grimesii / YeeX mutant strains carrying genes encoding mutant YeeX protein homologues (SEQ ID NO: 12) To amplify the full-length nucleic acid sequence (SEQ ID NO: 43) containing the 840 bp upstream region of the gene encoding the wild-type YeeX protein homolog in the genome of the S. grimeii strain, the gene encoding the mutant YeeX protein homolog set forth in SEQ ID NO: 12, and the 840 bp downstream region of the gene encoding the wild-type YeeX protein homolog, PCR was performed according to standard methods using primers set forth in SEQ ID NOs: 20 and 21. The resulting fragment was purified by agarose gel electrophoresis and a nucleic acid column purification kit (Cytiva) and used to generate mutant strains.

[0075] The nucleic acid fragment (SEQ ID NO: 43) was introduced by electroporation into the S. grimesii / yeeX-deficient strain harboring the pKD46 plasmid prepared in Comparative Example 2. After introduction, the strain was cultured at 30°C on Medium I agar containing 50 g / L of sucrose. The resulting colonies were cultured at 30°C on LB agar and LB agar containing 25 μg / mL of kanamycin, and strains lacking kanamycin resistance were selected. The resulting strain was an S. grimesii / YeeX mutant strain in which the gene encoding a YeeX protein homolog (SEQ ID NO: 2) in which the alanine at position 84 in the amino acid sequence of SEQ ID NO: 1 on the genome was not substituted with a gene encoding a mutant YeeX protein homolog (SEQ ID NO: 12) in which the alanine at position 84 in the amino acid sequence of SEQ ID NO: 1 was substituted with valine.

[0076] The strain was cultured in the same manner as in Comparative Example 1, and the culture medium was centrifuged to obtain a supernatant, which was then passed through a Millex-GV membrane (0.22 μm, PVDF, manufactured by Merck). The permeate was analyzed by HPLC and LC-MS / MS. The results of quantitative analysis of the organic acids accumulated in the culture supernatant and the yield of the organic acids calculated using formula (2) are shown in Table 3.

[0077] (Comparative Example 3) Preparation and cultivation of S. grimesii strains carrying plasmid 1 Plasmid 1 prepared in Reference Example 2 was introduced by electroporation into the S. grimesii strain described in Comparative Example 1. After introduction, the strain was cultured at 30°C on LB agar medium containing 25 μg / mL of kanamycin. The resulting recombinant strain was designated S. grimesii / plasmid 1 strain.

[0078] The strain was cultured in the same manner as in Comparative Example 2, and the culture medium was centrifuged to obtain a supernatant, which was then passed through a Millex-GV membrane (0.22 μm, PVDF, manufactured by Merck). The permeate was analyzed by HPLC and LC-MS / MS. The results of quantitative analysis of the organic acids accumulated in the culture supernatant and the yield of the organic acids calculated using formula (2) are shown in Table 3.

[0079] (Example 2) Construction and cultivation of S. grimeii / YeeX mutant strain carrying plasmid 1 Plasmid 1 prepared in Reference Example 2 was introduced by electroporation into the S. grimesii / YeeX mutant strain prepared in Example 1. After introduction, the strain was cultured at 30°C on LB agar medium containing 25 μg / mL of kanamycin. The resulting recombinant strain was designated S. grimesii / plasmid 1 / YeeX mutant strain.

[0080] The strain was cultured in the same manner as in Comparative Example 2, and the culture medium was centrifuged to obtain a supernatant, which was then passed through a Millex-GV membrane (0.22 μm, PVDF, manufactured by Merck). The permeate was analyzed by HPLC and LC-MS / MS. The results of quantitative analysis of the organic acids accumulated in the culture supernatant and the yield of the organic acids calculated using formula (2) are shown in Table 3.

[0081] (Example 3) Construction and cultivation of S. grimesii strains carrying plasmids 1 and 3 Plasmid 3 prepared in Reference Example 4 was introduced by electroporation into the S. grimesii / plasmid 1 strain prepared in Comparative Example 3. After introduction, the strain was cultured at 30°C on LB agar medium containing 25 μg / mL kanamycin and 500 μg / mL ampicillin. The resulting recombinant strain was designated S. grimesii / plasmid 1 / plasmid 3 strain.

[0082] A loopful of the strain was inoculated into 5 mL of LB medium (10 g / L Bacto tryptone (Difco Laboratories), 5 g / L Bacto yeast extract (Difco Laboratories), 5 g / L sodium chloride) containing 25 μg / mL kanamycin and 500 μg / mL ampicillin adjusted to pH 7, and cultured at 30°C with shaking at 120 min-1 for 18 hours. 0.15 mL of the culture medium was added to 15 mL of Medium I (glucose 10 g / L, ammonium sulfate 1 g / L, potassium phosphate 50 mM, magnesium sulfate 0.025 g / L, iron sulfate 0.0625 mg / L, manganese sulfate 2.7 mg / L, calcium chloride 0.33 mg / L, sodium chloride 1.25 g / L, Bacto tryptone 2.5 g / L, Bacto yeast extract 1.25 g / L) containing 25 μg / mL kanamycin and 500 μg / mL ampicillin adjusted to pH 6.5 in a screw-capped test tube, and the mixture was cultured at 30°C with shaking at 120 min-1 for 48 hours.

[0083] The supernatant obtained by centrifuging the culture medium and separating the cells was passed through a Millex-GV membrane (0.22 μm, PVDF, Merck), and the permeate was analyzed by HPLC and LC-MS / MS. The results of quantitative analysis of the organic acids accumulated in the culture supernatant and the yield of the organic acids calculated using formula (2) are shown in Table 3.

[0084] (Comparative Example 4) Preparation and cultivation of S. grimesii strains carrying plasmids 1 and 2 Plasmid 2 prepared in Reference Example 3 was introduced by electroporation into the S. grimesii / plasmid 1 strain prepared in Comparative Example 3. After introduction, the strain was cultured at 30°C on LB agar medium containing 25 μg / mL kanamycin and 500 μg / mL ampicillin. The resulting recombinant strain was designated S. grimesii / plasmid 1 / plasmid 2 strain.

[0085] The strain was cultured in the same manner as in Example 3, and the culture medium was centrifuged to obtain a supernatant, which was then passed through a Millex-GV membrane (0.22 μm, PVDF, manufactured by Merck). The permeate was analyzed by HPLC and LC-MS / MS. The results of quantitative analysis of the organic acids accumulated in the culture supernatant and the yield of the organic acids calculated using formula (2) are shown in Table 3.

[0086] (Example 4) Construction and cultivation of S. grimeii / YeeX mutant strains carrying plasmids 1 and 2 Plasmid 2 prepared in Reference Example 3 was introduced by electroporation into the S. grimesii / YeeX mutant strain prepared in Example 1. After introduction, the strain was cultured at 30°C on LB agar medium containing 25 μg / mL kanamycin and 500 μg / mL ampicillin. The resulting recombinant strain was designated S. grimesii / plasmid 1 / plasmid 2 / YeeX mutant strain.

[0087] The strain was cultured in the same manner as in Example 3, and the culture medium was centrifuged to obtain a supernatant, which was then passed through a Millex-GV membrane (0.22 μm, PVDF, manufactured by Merck). The permeate was analyzed by HPLC and LC-MS / MS. The results of quantitative analysis of the organic acids accumulated in the culture supernatant and the yield of the organic acids calculated using formula (2) are shown in Table 3.

[0088] [Table 3]

[0089] The results of Comparative Examples 1 and 2 and Example 1 revealed that the S. grimesii / YeeX mutant strain, which has a gene encoding a mutant YeeX protein homolog (sequence number 12) on its genome, produces organic acids such as succinic acid and acetic acid at a higher yield than the S. grimesii parent strain and the S. grimesii / YeeX-deficient strain, which have a gene encoding a wild-type YeeX protein homolog (sequence number 2) on their genome.

[0090] The results of Comparative Example 3 and Example 2 showed that the S. grimeii / plasmid 1 / YeeX mutant strain carrying plasmid 1, which expresses the enzymes necessary for 3HA production, also had improved fermentation production yields of organic acids such as succinic acid, acetic acid, 3HA, and HMA compared to the parent strain carrying plasmid 1.

[0091] In Example 3, an improvement in organic acid yield was also observed in the S. grimesii / plasmid 1 / plasmid 3 strain, which has a gene encoding a wild-type YeeX protein homolog (SEQ ID NO: 2) on its genome and carries plasmids 3 and 1 expressing a mutant YeeX protein homolog (SEQ ID NO: 12). This demonstrates that the effects of the present invention can be obtained even in an S. grimesii strain into which a mutant YeeX protein homolog has been introduced using an expression plasmid and in which both a wild-type YeeX protein homolog and a mutant YeeX protein homolog are expressed.

[0092] The results of Comparative Example 4 and Example 4 showed that the S. grimeii / plasmid 1 / plasmid 2 / YeeX mutant strain carrying plasmids 1 and 2 that express the enzymes necessary for ADA production also showed significantly improved yields of organic acids such as succinic acid, acetic acid, 3HA, HMA, and ADA, compared to the parent strain carrying plasmids 1 and 2.

[0093] (Comparative Example 5) Cultivation of E. coli strains carrying the gene encoding the wild-type YeeX protein (SEQ ID NO: 1) The Escherichia coli MG1655 strain was used as a parent strain carrying the wild-type YeeX protein set forth in SEQ ID NO: 1. This strain was cultured in the same manner as in Comparative Example 1, and the culture medium was centrifuged to remove the bacterial cells. The supernatant was then passed through a Millex-GV membrane (0.22 μm, PVDF, Merck), and the permeate was analyzed by HPLC and LC-MS / MS. The results of quantitative analysis of the organic acids accumulated in the culture supernatant and the yield of the organic acids calculated using formula (2) are shown in Table 4.

[0094] (Comparative Example 6) Preparation and cultivation of E. coli / yeeX-deficient strain lacking the gene encoding the YeeX protein The pKD46 plasmid required for expressing λ Red recombinase was introduced into the E. coli strain described in Comparative Example 5 by electroporation. After introduction, the strain was cultured at 30°C on LB agar medium containing 50 μg / mL of ampicillin. The nucleic acid fragment prepared in Reference Example 5 was introduced into the resulting strain by electroporation. After introduction, the strain was cultured at 30°C on LB agar medium containing 25 μg / mL of kanamycin. The resulting recombinant strain was an E. coli / pKD46 / yeeX-deficient strain in which the full-length gene sequence encoding YeeX had been replaced with a recombination cassette sequence. To remove the pKD46 plasmid from the E. coli / pKD46 / yeeX-deficient strain, one loopful of the strain was inoculated into 5 mL of LB medium (10 g / L Bacto tryptone (Difco Laboratories), 5 g / L Bacto yeast extract (Difco Laboratories), 5 g / L sodium chloride) and cultured at 37°C for 48 hours with shaking at 120 min-1. Ten μL of the culture was cultured on LB agar medium at 30°C, and colonies lacking ampicillin resistance were selected to obtain the E. coli / yeeX-deficient strain.

[0095] The strain was cultured in the same manner as in Comparative Example 2, and the culture medium was centrifuged to obtain a supernatant, which was then passed through a Millex-GV membrane (0.22 μm, PVDF, manufactured by Merck). The permeate was analyzed by HPLC and LC-MS / MS. The results of quantitative analysis of the organic acids accumulated in the culture supernatant and the yield of the organic acids calculated using formula (2) are shown in Table 4.

[0096] (Example 5) Preparation and cultivation of E. coli / YeeX mutant strains carrying genes encoding mutant YeeX proteins (SEQ ID NO: 44) To amplify the full-length nucleic acid sequence (SEQ ID NO: 48) containing a 500-b upstream region of the gene encoding the wild-type YeeX protein (SEQ ID NO: 1) in the genome of the E. coli strain, a PCR reaction was performed according to standard methods using primers represented by SEQ ID NOs: 46 and 47. The resulting fragment was purified by agarose gel electrophoresis and a nucleic acid column purification kit (Cytiva) and used to generate mutant strains.

[0097] The nucleic acid fragment (SEQ ID NO: 48) was introduced by electroporation into the E. coli / yeeX-deficient strain harboring the pKD46 plasmid prepared in Comparative Example 6. After introduction, the strain was cultured at 30°C on Medium I agar containing 50 g / L of sucrose. The resulting colonies were cultured at 30°C on LB agar medium and LB agar medium containing 25 μg / mL of kanamycin, and strains lacking kanamycin resistance were selected. The resulting strain was an E. coli / YeeX mutant strain in which the gene encoding the wild-type YeeX protein of SEQ ID NO: 1 on the genome had been replaced with a gene encoding a mutant YeeX protein (SEQ ID NO: 44) in which alanine at position 84 in the amino acid sequence of SEQ ID NO: 1 had been replaced with valine.

[0098] The strain was cultured in the same manner as in Comparative Example 1, and the culture medium was centrifuged to obtain a supernatant, which was then passed through a Millex-GV membrane (0.22 μm, PVDF, manufactured by Merck). The permeate was analyzed by HPLC and LC-MS / MS. The results of quantitative analysis of the organic acids accumulated in the culture supernatant and the yield of the organic acids calculated using formula (2) are shown in Table 4.

[0099] (Comparative Example 7) Preparation and cultivation of E. coli strains carrying plasmid 1 Plasmid 1 prepared in Reference Example 2 was introduced by electroporation into the E. coli strain described in Comparative Example 5. After introduction, the strain was cultured at 30°C on LB agar medium containing 25 μg / mL of kanamycin. The resulting recombinant strain was designated E. coli / plasmid 1 strain.

[0100] The strain was cultured in the same manner as in Comparative Example 2, and the culture medium was centrifuged to obtain a supernatant, which was then passed through a Millex-GV membrane (0.22 μm, PVDF, manufactured by Merck). The permeate was analyzed by HPLC and LC-MS / MS. The results of quantitative analysis of the organic acids accumulated in the culture supernatant and the yield of the organic acids calculated using formula (2) are shown in Table 4.

[0101] (Example 6) Construction and cultivation of E. coli / YeeX mutant strain carrying plasmid 1 Plasmid 1 prepared in Reference Example 2 was introduced by electroporation into the E. coli / YeeX mutant strain prepared in Example 5. After introduction, the strain was cultured at 30°C on LB agar medium containing 25 μg / mL of kanamycin. The resulting recombinant strain was designated E. coli / plasmid 1 / YeeX mutant strain.

[0102] The strain was cultured in the same manner as in Comparative Example 2, and the culture medium was centrifuged to obtain a supernatant, which was then passed through a Millex-GV membrane (0.22 μm, PVDF, manufactured by Merck). The permeate was analyzed by HPLC and LC-MS / MS. The results of quantitative analysis of the organic acids accumulated in the culture supernatant and the yield of the organic acids calculated using formula (2) are shown in Table 4.

[0103] (Example 7) Construction and cultivation of E. coli strains carrying plasmids 1 and 4 Plasmid 4 prepared in Reference Example 6 was introduced by electroporation into the E. coli / plasmid 1 strain prepared in Comparative Example 7. After introduction, the strain was cultured at 30°C on LB agar medium containing 25 μg / mL kanamycin and 50 μg / mL streptomycin. The resulting recombinant strain was designated E. coli / plasmid 1 / plasmid 4 strain.

[0104] A loopful of the strain was inoculated into 5 mL of LB medium (10 g / L Bacto tryptone (Difco Laboratories), 5 g / L Bacto yeast extract (Difco Laboratories), 5 g / L sodium chloride) containing 25 μg / mL kanamycin and 50 μg / mL streptomycin adjusted to pH 7, and cultured at 30°C for 18 hours with shaking at 120 min-1. 0.15 mL of the culture medium was added to 15 mL of Medium I (glucose 10 g / L, ammonium sulfate 1 g / L, potassium phosphate 50 mM, magnesium sulfate 0.025 g / L, iron sulfate 0.0625 mg / L, manganese sulfate 2.7 mg / L, calcium chloride 0.33 mg / L, sodium chloride 1.25 g / L, Bacto tryptone 2.5 g / L, Bacto yeast extract 1.25 g / L) containing 25 μg / mL kanamycin and 50 μg / mL streptomycin and adjusted to pH 6.5 in a screw-capped test tube, and the mixture was cultured at 30°C with shaking at 120 min-1 for 48 hours.

[0105] The supernatant obtained by centrifuging the culture medium and separating the cells was passed through a Millex-GV membrane (0.22 μm, PVDF, manufactured by Merck), and the permeate was analyzed by HPLC and LC-MS / MS. The results of quantitative analysis of the organic acids accumulated in the culture supernatant and the yield of the organic acids calculated using formula (2) are shown in Table 4.

[0106] (Comparative Example 8) Preparation and cultivation of E. coli strains carrying plasmids 1 and 2 Plasmid 2 prepared in Reference Example 3 was introduced by electroporation into the E. coli / plasmid 1 strain prepared in Comparative Example 7. After introduction, the strain was cultured at 30°C on LB agar medium containing 25 μg / mL kanamycin and 50 μg / mL ampicillin. The resulting recombinant strain was designated E. coli / plasmid 1 / plasmid 2 strain.

[0107] One loopful of the strain was inoculated into 5 mL of LB medium (Bacto tryptone (Difco Laboratories) 10 g / L, Bacto yeast extract (Difco Laboratories) 5 g / L, sodium chloride 5 g / L) containing 25 μg / mL kanamycin and 50 μg / mL ampicillin adjusted to pH 7, and cultured at 30°C with shaking at 120 min-1 for 18 hours. 0.15 mL of the culture medium was added to 15 mL of Medium I (glucose 10 g / L, ammonium sulfate 1 g / L, potassium phosphate 50 mM, magnesium sulfate 0.025 g / L, iron sulfate 0.0625 mg / L, manganese sulfate 2.7 mg / L, calcium chloride 0.33 mg / L, sodium chloride 1.25 g / L, Bacto tryptone 2.5 g / L, Bacto yeast extract 1.25 g / L) containing 25 μg / mL kanamycin and 50 μg / mL ampicillin adjusted to pH 6.5 in a screw-capped test tube, and the mixture was cultured at 30°C with shaking at 120 min-1 for 48 hours.

[0108] The supernatant obtained by centrifuging the culture medium and separating the cells was passed through a Millex-GV membrane (0.22 μm, PVDF, manufactured by Merck), and the permeate was analyzed by HPLC and LC-MS / MS. The results of quantitative analysis of the organic acids accumulated in the culture supernatant and the yield of the organic acids calculated using formula (2) are shown in Table 4.

[0109] (Example 8) Construction and cultivation of E. coli / YeeX mutant strains carrying plasmids 1 and 2 Plasmid 2 prepared in Reference Example 3 was introduced by electroporation into the E. coli / YeeX mutant strain prepared in Example 5. After introduction, the strain was cultured at 30°C on LB agar medium containing 25 μg / mL kanamycin and 50 μg / mL ampicillin. The resulting recombinant strain was designated E. coli / plasmid 1 / plasmid 2 / YeeX mutant strain.

[0110] The strain was cultured in the same manner as in Comparative Example 8, and the culture medium was centrifuged to obtain a supernatant, which was then passed through a Millex-GV membrane (0.22 μm, PVDF, manufactured by Merck), and the permeate was analyzed by HPLC and LC-MS / MS. The results of quantitative analysis of the organic acids accumulated in the culture supernatant and the yield of the organic acids calculated using formula (2) are shown in Table 4.

[0111] [Table 4]

[0112] The results of Comparative Examples 5 and 6 and Example 5 revealed that the E. coli / YeeX mutant strain carrying a gene encoding the mutant YeeX protein (sequence number 44) on its genome produces organic acids such as succinic acid and acetic acid at a higher yield than the parent E. coli strain carrying a gene encoding the wild-type YeeX protein (sequence number 1) on its genome or the E. coli / YeeX-deficient strain.

[0113] The results of Comparative Example 7 and Example 6 showed that the E. coli / plasmid 1 / YeeX mutant strain carrying plasmid 1, which expresses the enzymes required for 3HA production, also had improved fermentation production yields of organic acids such as succinic acid, acetic acid, and 3HA compared to the parent strain carrying plasmid 1.

[0114] In Example 6, an improvement in organic acid yield was also observed in the E. coli / plasmid 1 / plasmid 4 strain, which contained a gene encoding the wild-type YeeX protein (SEQ ID NO: 1) on its genome and plasmids 4 and 1 expressing the mutant YeeX protein (SEQ ID NO: 44). This demonstrates that the effects of the present invention can be achieved even in E. coli strains in which mutant YeeX is introduced using an expression plasmid and both wild-type and mutant YeeX proteins are expressed.

[0115] The results of Comparative Example 8 and Example 8 showed that the E. coli / plasmid 1 / plasmid 2 / YeeX mutant strain carrying plasmids 1 and 2 that express the enzymes necessary for ADA production also showed significantly improved yields of organic acids such as succinic acid, acetic acid, 3HA, HMA, and ADA, compared to the parent strain carrying plasmids 1 and 2.

Claims

1. A genetically modified microorganism belonging to the genus Escherichia, into which a gene encoding a CoA transferase has been introduced, said microorganism comprising a gene capable of expressing a mutant YeeX protein, the gene comprising an amino acid sequence having 90% or more sequence identity to the amino acid sequence represented by SEQ ID NO: 1, and having a mutation in which alanine, the amino acid corresponding to position 84 in the amino acid sequence of SEQ ID NO: 1, is substituted with another amino acid, said gene having the function of improving the ability of a microorganism of the genus Escherichia to produce succinic acid, acetic acid, 3-hydroxyadipic acid, α-hydromuconic acid and / or adipic acid when said gene is introduced into said microorganism, said microorganism being capable of producing succinic acid, acetic acid, 3-hydroxyadipic acid, α-hydromuconic acid and / or adipic acid, compared to the microorganism prior to introduction.

2. A genetically modified microorganism belonging to the genus Serratia, into which a gene encoding a CoA transferase has been introduced, said microorganism comprising a gene capable of expressing a mutant YeeX protein consisting of the amino acid sequence represented by SEQ ID NO: 2, and having a mutation in which alanine at position 87 in the amino acid sequence of SEQ ID NO: 2 has been substituted with another amino acid, said gene having the function of improving the ability of a microorganism of the genus Serratia to produce succinic acid, acetic acid, 3-hydroxyadipic acid, α-hydromuconic acid and / or adipic acid when said gene is introduced into said microorganism, said microorganism being capable of producing succinic acid, acetic acid, 3-hydroxyadipic acid, α-hydromuconic acid and / or adipic acid, compared to the microorganism prior to introduction.

3. 2. The genetically modified microorganism of claim 1, wherein the mutant YeeX protein has a mutation in which the alanine corresponding to the 84th amino acid in the amino acid sequence of SEQ ID NO: 1 is replaced with valine, leucine, phenylalanine, isoleucine, or methionine.

4. A genetically modified microorganism as described in claim 2, wherein the mutant YeeX protein has a mutation in which the 87th alanine in the amino acid sequence of SEQ ID NO: 2 is replaced with valine, leucine, phenylalanine, isoleucine, or methionine.

5. The genetically modified microorganism according to any one of claims 1 to 4, which has on its genome a gene capable of expressing the mutant YeeX protein.

6. 6. The genetically modified microorganism according to claim 5, wherein a gene capable of expressing a YeeX protein on the genome has been mutated or substituted with a gene capable of expressing the mutant YeeX protein.

7. A method for producing an organic acid, comprising culturing the genetically modified microorganism according to any one of claims 1 to 6 in a medium containing a carbon source as a fermentation raw material.

8. 8. The method for producing an organic acid according to claim 7, wherein the organic acid is succinic acid, acetic acid, 3-hydroxyadipic acid, α-hydromuconic acid, and / or adipic acid.

9. A genetically modified microorganism belonging to the genus Escherichia, comprising a gene capable of expressing a mutant YeeX protein, the gene consisting of an amino acid sequence that has a sequence identity of 90% or more to the amino acid sequence represented by SEQ ID NO: 1, and having a mutation in which alanine, the amino acid corresponding to the 84th amino acid in the amino acid sequence of SEQ ID NO: 1, is substituted with another amino acid, and the gene has the function of improving the ability of a microorganism of the genus Escherichia to produce succinic acid, acetic acid, 3-hydroxyadipic acid, α-hydromuconic acid and / or adipic acid, when the gene is introduced into the microorganism, compared to the microorganism before introduction.

10. A genetically modified microorganism belonging to the genus Serratia, comprising a gene capable of expressing a mutant YeeX protein consisting of the amino acid sequence represented by SEQ ID NO: 2 and having a mutation in which alanine at position 87 in the amino acid sequence of SEQ ID NO: 2 is substituted with another amino acid, wherein when the gene is introduced into a microorganism of the genus Serratia capable of producing succinic acid, acetic acid, 3-hydroxyadipic acid, α-hydromuconic acid and / or adipic acid, the microorganism has the function of improving the ability to produce succinic acid, acetic acid, 3-hydroxyadipic acid, α-hydromuconic acid and / or adipic acid compared to the microorganism before the introduction.

11. 10. The genetically modified microorganism of claim 9, wherein the mutant YeeX protein has a mutation in which the alanine corresponding to the 84th amino acid in the amino acid sequence of SEQ ID NO: 1 is replaced with valine, leucine, phenylalanine, isoleucine, or methionine.

12. A genetically modified microorganism as described in claim 10, wherein the mutant YeeX protein has a mutation in which the 87th alanine in the amino acid sequence of SEQ ID NO: 2 is replaced with valine, leucine, phenylalanine, isoleucine, or methionine.

13. A method for producing an organic acid, comprising culturing the genetically modified microorganism according to any one of claims 9 to 12 in a medium containing a carbon source as a fermentation raw material.

14. The method for producing an organic acid according to claim 13, wherein the organic acid is succinic acid, acetic acid, 3-hydroxyadipic acid, α-hydromuconic acid and / or adipic acid.

Citation Information

Patent Citations

  • Method for producing organic acid

    JP2017192325A

  • Molecules Involved in Protein Folding

    US20070298418A1

  • Gene-modified microorganism for producing 3-hydroxyadipic acid, α-hydromuconic acid and / or adipic acid, and production method for said chemical products

    WO2019107516A1